Saturday 17 October 2026
Export TRAW’s income statement to Excel — free account
Traws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 1.78% and free cash flow fell 25.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.37
0.03
−7.50%
Follow TRAW
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
1.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 3 | 3 | 3 | 3 | 2 | 4 | 3 | 2 | 2 |
P/S ratio |
3.27 | 61.01 | 73.37 | 65.68 | 189.92 | 354.10 | 2.51 | 7.09 | 17.15 | 1.80 |
Altman Z-Score |
(89.55) | (54.43) | (31.23) | (16.44) | (8.38) | (30.00) | (25.75) | (33.01) | (119.49) | (22.50) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(209.84) | (120.17) | (70.56) | (33.84) | (17.12) | (74.63) | (56.50) | (74.33) | (279.37) | (50.37) |
Beneish M-Score |
2,517.31 | 61.01 | (3.09) | (3.40) | (2.62) | (2.91) | (1.00) | (0.69) | 7.38 | (4.88) |
P/Operating CF |
(3.37) | (3.41) | (3.74) | (3.82) | (10.06) | (14.96) | (1.02) | (1.61) | (2.89) | (2.29) |
P/B ratio |
0.00 | 0.00 | 1.55 | 0.52 | 0.93 | 13.25 | 0.47 | 1.62 | 0.00 | 1.95 |
Price to Tangible BV |
0.00 | 0.00 | 1.55 | 0.52 | 0.93 | 13.25 | 0.47 | 1.62 | 0.00 | 1.95 |
EV/Sales |
1.92 | (33.41) | (18.76) | (105.81) | (53.75) | 271.74 | (7.90) | (6.73) | 12.04 | (2.07) |
EV/EBITDA |
0.00 | 0.05 | 0.21 | 1.22 | 0.74 | 0.00 | 0.80 | 0.36 | 0.00 | 0.49 |
EV/Operating CF |
(0.30) | 0.25 | 0.24 | 1.47 | 0.62 | (2.72) | 0.83 | 0.36 | (0.40) | 0.72 |
EV/FCF |
(0.30) | 0.25 | 0.24 | 1.47 | 0.62 | (2.72) | 0.83 | 0.36 | (0.39) | 0.71 |
Quick Ratio |
0.68 | 2.00 | 2.26 | 4.82 | 9.01 | 1.90 | 2.75 | 2.02 | 0.41 | 2.11 |
Current Ratio |
0.72 | 2.16 | 2.46 | 4.89 | 9.06 | 1.97 | 2.83 | 2.11 | 0.49 | 2.27 |
Net Debt/EBITDA |
0.21 | 0.15 | 1.03 | 1.98 | 3.34 | 0.76 | 1.05 | 0.73 | 0.16 | 0.91 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.16 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.11 | 0.11 | 0.06 | 0.24 |
Operating CF/Net income |
(2.65) | 0.54 | 0.95 | 0.86 | 1.21 | 0.92 | 0.97 | 1.10 | 0.99 | 0.80 |
Capex/Depreciation |
(42.38) | 0.00 | (0.87) | 0.00 | 0.00 | (1.15) | (3.93) | 0.00 | 0.00 | 0.00 |
| (42.56%) | 521.75% | (97.22%) | (50.96%) | (61.81%) | (283.48%) | (253.56%) | 751.66% | 840.32% | (246.35%) | |
| 38.59% | (229.51%) | (61.07%) | (39.99%) | (42.84%) | (115.24%) | (103.39%) | (179.66%) | (170.79%) | (84.27%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(217.25%) | (407.16%) | (140.75%) | (60.54%) | (32.75%) | (256.31%) | (141.17%) | (220.36%) | 480.97% | (150.58%) |
Average Days of Receivables |
496.35 | 2,850.55 | 29.07 | 46.84 | 45.22 | 58.46 | 16.39 | 10.40 | 27.36 | 2.04 |
Research and Development Expense of Revenue |
435.23% | 57,659.73% | 5,057.52% | 5,046.90% | 3,228.76% | 7,315.15% | 711.73% | 1,378.18% | 2,429.35% | 361.90% |
Selling, General and Administrative Expense of Revenue |
305.45% | 5,437.61% | 4,023.89% | 3,737.61% | 4,170.35% | 3,604.33% | 382.27% | 617.75% | 940.91% | 165.49% |
Intangible Assets out of Total Assets |
0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
26.09% | 615.04% | 575.66% | 518.58% | 254.87% | 159.74% | 48.01% | 93.40% | 217.28% | 70.84% |
Graham Net Nets |
(0.35) | (2.29) | 0.64 | 1.91 | 1.07 | 0.07 | 2.08 | 0.60 | (0.81) | 0.50 |
Graham Number |
0.00 | 136.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49,184.29 | 0.00 |
Earnings Yield |
83.43% | (460.59%) | (115.19%) | (128.17%) | (37.25%) | (27.65%) | (393.96%) | (375.82%) | (187.72%) | (246.93%) |
Free Cash Flow Yield |
(195.73%) | (216.17%) | (108.23%) | (109.86%) | (45.43%) | (28.23%) | (381.80%) | (263.38%) | (178.13%) | (160.57%) |
Revenue per Share |
0.34 | 0.15 | 0.27 | 0.27 | 0.34 | 0.50 | 56.85 | 111.64 | 491.88 | 6,932.50 |
Operating CF per Share |
(2.21) | (19.19) | (21.36) | (19.48) | (28.94) | (49.72) | (542.47) | (2,063.27) | (14,887.50) | (19,766.25) |
Capex per Share |
(0.31) | 0.00 | (0.02) | 0.00 | 0.00 | (0.03) | (1.43) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.52) | (19.19) | (21.37) | (19.48) | (28.94) | (49.75) | (543.91) | (2,063.27) | (14,887.50) | (19,766.25) |
Cash per Share |
0.46 | 13.74 | 24.80 | 46.34 | 81.79 | 40.99 | 591.82 | 1,542.73 | 2,515.00 | 26,812.50 |
Shareholders Equity per Share |
(0.08) | (20.37) | 12.71 | 33.85 | 68.50 | 13.31 | 301.41 | 489.73 | (6,788.12) | 6,408.75 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.08) | (20.37) | 12.71 | 33.85 | 68.50 | 13.31 | 301.41 | 489.73 | (6,788.12) | 6,408.75 |
Free Cash Flow |
(20.77) | (29.79) | (17.95) | (16.29) | (19.49) | (23.09) | (20.89) | (22.70) | (23.82) | (15.81) |
Working Capital |
(3.17) | 13.42 | 13.44 | 31.30 | 49.32 | 9.76 | 15.18 | 9.33 | (5.07) | 12.91 |
Capital Expenditures |
(2.58) | — | (0.01) | — | — | (0.01) | (0.05) | — | — | — |
Net Current Asset Value |
(3.27) | (31.64) | 10.65 | 28.28 | 46.07 | 5.97 | 11.37 | 5.23 | (10.94) | 4.96 |
EV/EBIT |
0.00 | 0.05 | 0.21 | 1.22 | 0.74 | 0.00 | 0.80 | 0.36 | 0.00 | 0.48 |
Capex to Sales |
0.93 | 0.00 | 0.06 | 0.00 | 0.00 | 0.06 | 0.03 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
8.71 | 1.20 | 0.73 | 0.58 | 0.37 | 0.25 | 0.28 | 6.11 | 1.38 | 0.63 |
Cash ROIC |
(650.89%) | 289.47% | (56.98%) | (24.30%) | (19.26%) | (91.63%) | (60.89%) | (101.52%) | 348.40% | (59.50%) |
Accounts Receivable Turnover |
1.00 | 0.25 | 9.62 | 7.93 | 6.95 | 3.42 | 32.83 | 26.13 | 17.49 | 7.23 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
2.78 | 0.89 | 0.02 | 0.03 | 0.03 | 0.07 | 0.07 | 0.05 | 0.05 | 0.77 |
Average Payables |
6.92 | 6.90 | 4.74 | 3.31 | 3.80 | 4.55 | 4.16 | 5.11 | 5.75 | 4.37 |
Average Assets |
17.79 | 23.82 | 31.03 | 47.43 | 37.73 | 21.83 | 20.80 | 11.45 | 14.11 | 23.34 |
Average Common Equity |
(16.13) | (10.48) | 19.49 | 37.21 | 26.15 | 8.87 | 8.48 | (2.74) | (2.87) | 7.98 |
Columns are period end dates